Clinical Trial Update: A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer [Phase 2]

View source ↗

Summary

This Phase 2 trial assesses the combination of tucatinib and trastuzumab deruxtecan in HER2-positive breast cancer; the study has completed and results were pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)
• Tukysa (tucatinib)

Snippet

Sponsor: Seagen, a wholly owned subsidiary of Pfizer | Conditions: HER2 Positive Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2025-07-31